Harnessing B7-H6 for Anticancer Immunotherapy: Expression, Pathways, and Therapeutic Strategies
Related Experiment Video
Updated: Jun 10, 2025
Immunohistochemical Staining of B7-H1 PD-L1 on Paraffin-embedded Slides of Pancreatic Adenocarcinoma Tissue
Published on: January 3, 2013
Sunyoung Lee1,2, Ji Hyun Kim1,3, In-Hwan Jang1
1Center for Cell and Gene Therapy, Korea Research Institute of Bioscience and Biotechnology (KRIBB), Daejeon 34141, Republic of Korea.
Abstract:
Cancer therapies have evolved from traditional chemotherapy to more precise molecular-targeted immunotherapies, which have been associated with improved side effects and outcomes. These modern strategies rely on cancer-specific biomarkers that differentiate malignant from normal cells. The B7 family of immune checkpoint molecules is crucial for cancer immune evasion and a prime therapeutic target. B7-H6, a recently identified member of the B7 family, has emerged as a promising therapeutic target. Unlike other B7 proteins, B7-H6 is not expressed in healthy tissues but is upregulated in several cancers. It binds to NKp30, activating natural killer (NK) cells and triggering immune responses against cancer cells. This review explores the expression of B7-H6 in different cancers, the factors that regulate its expression, and its intrinsic and extrinsic pathways. Additionally, we discuss potential anticancer therapies targeting B7-H6, highlighting its significance in advancing precision medicine. Understanding the role of B7-H6 in cancer immunity may inform the development of appropriate therapies that exploit its cancer-specific expression.
Insights
B7-H6 is a promising cancer biomarker, not found in healthy tissues but present in tumors. Targeting B7-H6 activates natural killer cells, offering a new avenue for precision cancer immunotherapy.
Area of Science:
- Immunology
- Oncology
- Molecular Biology
Background:
- Modern cancer immunotherapies leverage cancer-specific biomarkers for targeted treatment.
- Immune checkpoint molecules, like the B7 family, are critical in cancer immune evasion.
- B7-H6 is a novel B7 family member, upregulated in various cancers but absent in healthy tissues.
Purpose of the Study:
- To review the expression patterns of B7-H6 across different cancer types.
- To explore the regulatory mechanisms and signaling pathways of B7-H6.
- To discuss the therapeutic potential of targeting B7-H6 in cancer treatment.
Main Methods:
- Literature review of studies on B7-H6 expression and function in cancer.
- Analysis of B7-H6's role in natural killer (NK) cell activation via NKp30.
- Exploration of intrinsic and extrinsic signaling pathways influenced by B7-H6.
Main Results:
- B7-H6 expression is cancer-specific, making it a valuable biomarker.
- B7-H6 binding to NKp30 activates NK cells, promoting anti-cancer immune responses.
- Understanding B7-H6 pathways provides insights into cancer immune evasion.
Conclusions:
- B7-H6 represents a significant therapeutic target for precision cancer immunotherapy.
- Targeting B7-H6 can harness the immune system to fight cancer, improving treatment outcomes.
- Further research into B7-H6 is crucial for developing novel anti-cancer strategies.
More Related Videos
11:08Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells
Published on: February 14, 2025
00:06An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
Published on: September 12, 2019
Related Concept Videos
01:27Tumor Immunotherapy
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...